UCB completes US synthetic peptide facility
UCB-Bioproducts has completed construction of its first US customer application laboratory.
UCB-Bioproducts has completed construction of its first US customer application laboratory.
The new cGMP pilot plant, located on an existing UCB site in South Carolina, will add flexibility to the company's manufacturing capabilities to produce synthetic peptide APIs from pre-clinical stages onwards. 'This new facility expands our current capacity and provides a stepping stone toward offering security of supply in two distinct sites in Europe and North America,' said Dr Alain Scarso, general manager of UCB-Bioproducts division. Both facilities will use the latest synthesis and downstream processing technologies.